REPL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.69%, SMA50 -7.16%, SMA200 -1.3%). The stock’s 14-day RSI is 46.02 (neutral), while the ATR of 0.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.03% below its high and over 186.94% above its low. Average 10-day trading volume of 3.67 million shares is below the 3-month average of 6.20 million, indicating normal recent market interest.

Replimune Group, Inc. has 78.06 million shares outstanding. The public float is 49.98 million shares, elevated short interest at 46.20% of float. This equals 19.20 million shares. The short ratio is 0.91 days. Institutional investors hold 100.13% of the float. Insiders own 2.72%. Omega Fund IV, L.P. holds 4.76 million shares, Stampacchia Otello has 4.67 million shares and Coffin Robert has 1.82 million shares. Over the past six months, insider transactions show net selling. They sold 113.00 thousand shares across 9 transactions.

Replimune Group, Inc. generated EPS of -$3.58 over the past year. Five-year average earnings growth is -14.85%. Wall Street analysts project EPS growth of 24.95% annually over the next five years. The latest quarter delivered EPS of -$0.77. The next quarter is forecast at -$0.70. Next year's EPS is expected at $5.46. Analyst sentiment is neutral. Analyst rating data shows there are 5 Strong Buy ratings, 3 Buy ratings, 9 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $22.00 to $2.00. The high target offers 370.09% upside. The low target suggests -57.26% downside. The mean target is $9.56. This offers 104.27% upside. Replimune Group, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended February 03, 2026, missed forecasts by 0.22%. The prior quarter beat by 3.45%. Over the last six quarters, Apple has recorded several small beats. These include -9.33% in November 12, 2024.

Replimune Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.43. This means the shares are trading above this model’s fair value.

Replimune Group, Inc. (NASDAQ:REPL) closed at $8.68 USD, gaining $4.00 (85.36%) from the previous close of $4.68. The stock is currently mid-range between its 52-week high and low $1.50 and $13.24. With a market capitalization of about $716.32 million, Replimune Group, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.12). Key stats such as the average daily volume over the past year has been around 6.19 million shares, trading with heavier-than-usual volume. Headquartered in Woburn, MA, Replimune Group, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sushil Patel, the company employs approximately 479 people and listed since July 20, 2018. Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.

Replimune Group, Inc. trades at a P/E ratio of -1.38, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.07 suggesting the stock is closer to book value. The P/FCF stands at -1.38, also above market averages.

Our AI price prediction model suggests that Replimune Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.21%, with price expected at $4.69 by June 11, 2026, within a range of $2.47 to $6.72 3-Month Outlook: Projected fall of -47.65%, reaching $2.45 by August 26, 2026, with a range of $1.91 to $2.98. 1-Year Outlook: Projected gain of 139.1%, with price at $11.19 by May 28, 2027, within a range of $3.34 to $16.05.

Replimune Group, Inc. (NASDAQ:REPL) shares are down -27.88% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Replimune Group, Inc. trading at a premium to the broader market with a P/E of -1.38. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $28.42, suggesting 507.26% upside. Our AI forecast model points to short-term strength (0.21% over two weeks), a medium-term fall (-47.65% over three months), and a longer-term gain (139.1% over one year), with expected trading ranges indicating moderate volatility.